Phaseline

Companies › Immuno Cure Holding (HK)

Immuno Cure Holding (HK): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ICVAX
PD-1-enhanced HIV therapeutic DNA vaccine
–Phase 1Human Immunodeficiency VirusMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07530198ICVAXPhase 1Human Immunodeficiency VirusInfectious diseaseMar 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.